Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Executive Summary

Broad spectrum antibiotic candidates for hospital use dominate the late-stage pipeline under the US FDA's Qualified Infectious Disease Product (QIDP) program, despite efforts to target limited populations of patients and pathogens.

Advertisement

Related Content

Melinta To Launch First Commercial Drug Baxdela Independently
Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms
Motif A Step Closer To Succeeding With Iclaprim After Phase III Success
Nabriva Wants To Try A Different Approach To Antibiotic Stewardship
Paratek Sees Broad Potential For Omadacycline After Second Phase III Win
The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Keeping Track: US FDA Files Another Pfizer Cancer Biologic And TMC's New Antibiotic
Shionogi Eyes ’17 US Cefiderocol Filing After New Results
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Plazomicin’s US Debut Pencilled In For 2018, Achaogen Now Searching For Ex-US Partner

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel